Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
07 March 2022 - 11:00PM
Business Wire
Secures rhNELL-1 Carrier for Bone Regeneration
Spine Fusion Product
Bone Biologics Corporation (NASDAQ: BBLG), a
developer of orthobiologic products for spine fusion markets,
announces it has entered into a supply agreement with MTF Biologics
for demineralized bone matrix (DBM). MTF Biologics is a global
nonprofit organization that provides one of the orthopedic
industry’s largest portfolios of allograft tissue.
Bone Biologics is developing a bone graft substitute product
consisting of rhNELL-1 and a carrier, to be supplied by MTF
Biologics, for the initiation and improvement of bone formation.
This supply agreement provides material for the company’s planned
30-patient pilot study, and later for its planned U.S. pivotal
study in spine fusion patients.
“This DBM supply agreement is an important milestone that allows
us to advance rhNELL-1 for the $3 billion spine fusion market, with
the goal of developing a product with compelling features and
benefits versus existing commercial products,” said Jeff Frelick,
chief executive officer of Bone Biologics. “As we prepare to
commence human clinical studies, we are delighted to partner with
MTF Biologics, a highly-regarded industry innovator whose bone
matrix will now comprise half of our combination product.”
About MTF Biologics MTF Biologics is a global nonprofit
organization that saves and heals lives by honoring donated gifts,
serving patients and advancing science. It provides unmatched
service, resources and expertise to donors and their loved ones who
give the gift of donation, people who depend on tissue and organ
transplants, healthcare providers, and clinicians and
scientists.
The International Institute for the Advancement of Medicine
(IIAM), a Division of MTF Biologics, honors donors of
non-transplantable organs by providing their gifts to the medical
research community to combat and cure diseases. Statline, also a
Division of MTF Biologics, provides specialized communications and
technology expertise to organ, tissue and eye procurement
organizations, as well as the hospitals and patients they serve.
MTF Biologics’ sister organization, Deutsches Institute for
Zell-und Gewebeersatz – DIZG (The German Institute for Cell and
Tissue Transplantation), expands its reach to patients across the
globe. For more information, please visit www.mtfbiologics.org.
About Bone Biologics Bone Biologics was founded to pursue
regenerative medicine for bone. The Company is undertaking
groundbreaking work with select strategic partners, building on
unprecedented research on the Nell-1 protein that has produced a
significant number of studies and publications in peer reviewed
scientific literature. Bone Biologics is currently focusing its
development efforts for its bone graft substitute product on bone
regeneration in spinal fusion and has rights to trauma and
osteoporosis applications. For more information, please visit
www.bonebiologics.com.
Forward-looking Statements Certain statements contained
in this press release, including, without limitation, statements
containing the words ‘'believes,'' "anticipates," "expects" and
words of similar import, constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve both known and
unknown risks and uncertainties. The Company's actual results may
differ materially from those anticipated in its forward-looking
statements as a result of a number of factors, including those
including the Company's ability to develop its proposed abuse
deterrent fentanyl transdermal system and other proposed products,
its ability to obtain patent protection for its abuse technology,
its ability to obtain the necessary financing to develop products
and conduct the necessary clinical testing, its ability to obtain
Federal Food and Drug Administration approval to market any product
it may develop in the United States and to obtain any other
regulatory approval necessary to market any product in other
countries, its ability to market any product it may develop, its
ability to create, sustain, manage or forecast its growth; its
ability to attract and retain key personnel; changes in the
Company's business strategy or development plans; competition;
business disruptions; adverse publicity and international, national
and local general economic and market conditions and risks
generally associated with an undercapitalized developing company,
as well as the risks contained under "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" in the Company's Form S-1, Form 10-K for the
year ended December 31, 2020 and the Company's other filings with
the Securities and Exchange Commission. Except as required by
applicable law, we undertake no obligation to revise or update any
forward-looking statements to reflect any event or circumstance
that may arise after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220307005113/en/
LHA Investor Relations Kim Sutton Golodetz 212-838-3777
kgolodetz@lhai.com
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Apr 2024 to May 2024
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From May 2023 to May 2024